MedTrace Logo

Cognitive Function in Obstructive Sleep Apnea

NCT07364318 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-01-23

No results posted yet for this study

Summary

Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegeneration. Previous studies have identified several associated comorbidities, including vascular dysfunction, metabolic alterations, and neuroinflammatory changes. However, the impact and underlying interplay of these pathophysiological mechanisms remain poorly understood due to the lack of integrated, multidimensional assessment. This prospective, observational, longitudinal cohort study aims to investigate cognition and OSA-related physiological and pathophysiological processes in 100 adults newly diagnosed with OSA, who have no history of chronic diseases (except for overweight and obesity) and are not receiving chronic medication. A subgroup of patients with moderate to severe OSA indicated for positive airway pressure (PAP) therapy will be followed to evaluate its long-term effects on cognitive function and related mechanisms. All participants will undergo polysomnography (PSG), comprehensive neuropsychological assessment, brain MRI with volumetric analysis, biomarker profiling from blood and saliva, and evaluation of endothelial function, baroreflex sensitivity, and gut microbiome composition at baseline and after 12 months. PAP adherence will be continuously monitored. The primary objective of this study is to characterize the profile of cognitive impairment associated with OSA. Secondary exploratory analyses will focus on factors contributing to neurocognitive dysfunction in OSA.

Conditions

  • OSA - Obstructive Sleep Apnea
  • Cognitive Functions

Sponsors & Collaborators

  • University Hospital Bratislava

    collaborator OTHER

  • Slovak Academy of Sciences

    collaborator OTHER_GOV

  • Comenius University

    lead OTHER

Principal Investigators

  • Peter Turcani, prof. MD PhD. · 1st Department of Neurology, Faculty of Medicine, Comenius University and University Hospital Bratislava, Slovakia

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-08-31
Completion
2027-12-31

Countries

  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07364318 on ClinicalTrials.gov